Analytical Comparison: VBI Vaccines Inc. (VBIV) vs. At Titan Pharmaceuticals, Inc. (TTNP)

The shares of VBI Vaccines Inc. have decreased by more than -53.75% this year alone. The shares recently went down by -2.61% or -$0.02 and now trades at $0.74. The shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), has slumped by -69.93% year to date as of 09/12/2019. The shares currently trade at $0.40 and have been able to report a change of -8.55% over the past one week.

The stock of VBI Vaccines Inc. and Titan Pharmaceuticals, Inc. were two of the most active stocks on Thursday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. These figures suggest that VBIV ventures generate a higher ROI than that of TTNP.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, VBIV’s free cash flow per share is a negative -0.41, while that of TTNP is also a negative -0.07.

Valuation

VBIV currently trades at a P/B of 0.95, and a P/S of 18.33 while TTNP trades at a P/S of 1.57. This means that looking at the earnings, book values and sales basis, VBIV is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of VBIV is currently at a -91.03% to its one-year price target of 8.25. Looking at its rival pricing, TTNP is at a -95.98% relative to its price target of 9.95.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), VBIV is given a 1.50 while 2.50 placed for TTNP. This means that analysts are more bullish on the outlook for TTNP stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for VBIV is 2.20 while that of TTNP is just 2.14. This means that analysts are more bullish on the forecast for TTNP stock.

Conclusion

The stock of VBI Vaccines Inc. defeats that of Titan Pharmaceuticals, Inc. when the two are compared, with VBIV taking 4 out of the total factors that were been considered. VBIV happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, VBIV is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for VBIV is better on when it is viewed on short interest.